Hormone Refractory Prostate Cancer Market Report 2026
Download Free Sample Buy Now
Hormone Refractory Prostate Cancer Market Global Report 2026 Market Report Infographic Image

Published : March 2026

Pages : 250

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Hormone Refractory Prostate Cancer Market Report 2026

Global Outlook – By Treatment Type (Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
Purchase This Report Download Sample PDF
Item added to cart!

Hormone Refractory Prostate Cancer Market Overview

• Hormone Refractory Prostate Cancer market size has reached to $8.12 billion in 2025

• Expected to grow to $13.09 billion in 2030 at a compound annual growth rate (CAGR) of 10%

• Growth Driver: A Growing Investment In Cancer Research Worldwide Is Fueling The Growth Of The Market Due To Increasing Focus On Advanced Therapies And Precision Treatment Development

• Market Trend: Advancement In Targeted Radioligand Therapy Gains Ground In Advancing Treatment For Resistant Prostate Cancer

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hormone Refractory Prostate Cancer Market?

Hormone-refractory prostate cancer (HRPC), also known as castration-resistant prostate cancer (CRPC), is a form of prostate cancer that continues to progress despite achieving low testosterone levels through androgen deprivation therapy (ADT). This progression may be indicated by rising prostate-specific antigen (PSA) levels, radiographic evidence of new or growing tumors, or worsening clinical symptoms. Hormone-refractory prostate cancer (HRPC) represents a more advanced and treatment-resistant stage of prostate cancer, often requiring additional systemic therapies beyond standard hormone suppression.

The main treatment types for hormone-refractory prostate cancer are chemotherapy, hormonal therapy, immunotherapy, radiation therapy, and surgery. Chemotherapy treats hormone-refractory prostate cancer by using powerful drugs to target cancer that no longer responds to hormone therapy and has spread. It is distributed through several distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and is used by various end users, including hospitals, ambulatory surgical centers, specialty clinics, and others.

Hormone Refractory Prostate Cancer Market Global Report 2026 Market Report bar graph

What Is The Hormone Refractory Prostate Cancer Market Size and Share 2026?

The hormone refractory prostate cancer market size has grown rapidly in recent years. It will grow from $8.12 billion in 2025 to $8.95 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to rising incidence of advanced prostate cancer, widespread adoption of androgen deprivation therapy, increased availability of chemotherapy agents, growing use of psa-based disease monitoring, expansion of oncology care infrastructure.

What Is The Hormone Refractory Prostate Cancer Market Growth Forecast?

The hormone refractory prostate cancer market size is expected to see strong growth in the next few years. It will grow to $13.09 billion in 2030 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to increasing development of targeted therapies, rising clinical trial activity in castration-resistant prostate cancer, growing demand for personalized oncology care, expansion of immuno-oncology pipelines, increasing healthcare expenditure on cancer treatments. Major trends in the forecast period include increasing adoption of precision oncology therapies, rising use of combination drug regimens, growing integration of biomarker-based treatment selection, expansion of immunotherapy applications in advanced prostate cancer, enhanced focus on personalized treatment pathways.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us

Global Hormone Refractory Prostate Cancer Market Segmentation

1) By Treatment Type: Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery

2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

3) By End-User: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

Subsegments:

1) By Chemotherapy: Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin

2) By Hormonal Therapy: Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists

3) By Immunotherapy: Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy

4) By Radiation Therapy: External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy

5) By Surgery: Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)

What Is The Driver Of The Hormone Refractory Prostate Cancer Market?

A growing investment in cancer research is expected to propel the growth of the hormone-refractory prostate cancer market going forward. Cancer research investment involves funding and resource support to advance innovative cancer detection, treatment, and prevention approaches. The cancer research investment is rising due to the increasing global cancer burden, which demands more effective and targeted treatments. Investment in cancer research drives innovation in treating hormone-refractory prostate cancer by enabling advanced therapies such as radioligand treatments and hormone inhibitors. It also funds clinical trials and biomarker research to enhance treatment precision and outcomes. For instance, in August 2024, according to the Cancer Research Institute (CRI), a US-based nonprofit organization dedicated to advancing immunotherapy research, invested around $22.8 million in the 2023–2024 fiscal year, funding 64 new grants to researchers from 42 institutions across seven countries. Therefore, growing investment in cancer research is driving the growth of the hormone-refractory prostate cancer market.

Key Players In The Global Hormone Refractory Prostate Cancer Market

Major companies operating in the hormone refractory prostate cancer market are Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc

Global Hormone Refractory Prostate Cancer Market Trends and Insights

Major companies operating in the hormone-refractory prostate cancer market are focusing on developing advanced therapies, such as intravenous radioligand therapy, to improve survival rates in patients with resistant forms of the disease. Intravenous radioligand therapy is a targeted treatment that uses radioactive molecules attached to ligands to identify and bind to cancer-specific markers. It destroys cancer cells internally while sparing surrounding healthy tissue. For instance, in March 2025, Novartis AG, a Switzerland-based pharmaceutical corporation, launched Pluvicto (lutetium Lu 177 vipivotide tetraxetan), which received approval from the Food and Drug Administration (FDA). It is designed for earlier use in patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with an androgen receptor pathway inhibitor (ARPI) and are appropriate to delay chemotherapy. The expanded indication, based on the Phase III PSMAfore trial, approximately triples the eligible patient population and showed that Pluvicto reduced the risk of radiographic progression or death by 59% and more than doubled median radiographic progression-free survival compared to a change in ARPI. Pluvicto is the first targeted radioligand therapy approved for use before chemotherapy in this setting, offering a new treatment option that delays disease progression with a favorable safety profile.

Need data on a specific region in this market?
Request Regional Data

What Are Latest Mergers And Acquisitions In The Hormone Refractory Prostate Cancer Market?

In June 2024, AstraZeneca, a UK-based biopharmaceutical company, acquired Fusion Pharmaceuticals Inc. for $2.4 billion. This acquisition aims to enhance AstraZeneca’s oncology portfolio by adding next-generation radioconjugate therapies, including FPI-2265 for metastatic castration-resistant prostate cancer (mCRPC), and to strengthen its capabilities in radiopharmaceutical research and development, manufacturing, and supply. Fusion Pharmaceuticals Inc. is a Canada-based clinical-stage biopharmaceutical company that provides treatment for metastatic castration-resistant prostate cancer.

Regional Outlook

North America was the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hormone Refractory Prostate Cancer Market?

The hormone-refractory prostate cancer (HRPC) market consists of revenues earned by entities by providing services such as oncology consultations, advanced imaging, molecular diagnostic testing, clinical trial participation, and palliative care. The market value includes the value of related goods sold by the service provider or included within the service offering. The hormone-refractory prostate cancer (HRPC) market also includes sales of next-generation androgen receptor inhibitors, radiopharmaceuticals, and bone health agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hormone Refractory Prostate Cancer Market Report 2026?

The hormone refractory prostate cancer market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hormone refractory prostate cancer industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abdul Wasay

Hormone Refractory Prostate Cancer Market Report Forecast Analysis

Report AttributeDetails
Market Size Value In 2026 $8.95 billion
Revenue Forecast In 2035 $13.09 billion
Growth Rate CAGR of 10.2% from 2026 to 2035
Base Year For Estimation 2025
Actual Estimates/Historical Data 2020-2025
Forecast Period 2026 - 2030 - 2035
Market Representation Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered Treatment Type, Distribution Channel, End-User
Regional Scope Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc
Customization ScopeRequest for Customization
Pricing And Purchase OptionsExplore Purchase Options

Table Of Contents

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Hormone Refractory Prostate Cancer Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Hormone Refractory Prostate Cancer Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Hormone Refractory Prostate Cancer Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Hormone Refractory Prostate Cancer Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Biotechnology, Genomics & Precision Medicine

4.1.2 Artificial Intelligence & Autonomous Intelligence

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Industry 4.0 & Intelligent Manufacturing

4.1.5 Sustainability, Climate Tech & Circular Economy

4.2. Major Trends

4.2.1 Increasing Adoption Of Precision Oncology Therapies

4.2.2 Rising Use Of Combination Drug Regimens

4.2.3 Growing Integration Of Biomarker-Based Treatment Selection

4.2.4 Expansion Of Immunotherapy Applications In Advanced Prostate Cancer

4.2.5 Enhanced Focus On Personalized Treatment Pathways

5. Hormone Refractory Prostate Cancer Market Analysis Of End Use Industries

5.1 Hospitals

5.2 Specialty Oncology Clinics

5.3 Ambulatory Surgical Centers

5.4 Cancer Research Institutes

5.5 Academic Medical Centers

6. Hormone Refractory Prostate Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hormone Refractory Prostate Cancer Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Hormone Refractory Prostate Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Hormone Refractory Prostate Cancer Market Size, Comparisons And Growth Rate Analysis

7.3. Global Hormone Refractory Prostate Cancer Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Hormone Refractory Prostate Cancer Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hormone Refractory Prostate Cancer Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hormone Refractory Prostate Cancer Market Segmentation

9.1. Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Chemotherapy, Hormonal Therapy, Immunotherapy, Radiation Therapy, Surgery

9.2. Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

9.3. Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Other End-Users

9.4. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Docetaxel, Cabazitaxel, Mitoxantrone, Estramustin

9.5. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Anti-Androgens, CYP17 Inhibitors, LHRH Agonists, LHRH Antagonists

9.6. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Cancer Vaccines, Immune Checkpoint Inhibitors, Adoptive Cell Therapy

9.7. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

External Beam Radiation Therapy (EBRT), Brachytherapy, Radionuclide Therapy

9.8. Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Radical Prostatectomy, Orchiectomy, Transurethral Resection Of The Prostate (TURP)

10. Hormone Refractory Prostate Cancer Market Regional And Country Analysis

10.1. Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hormone Refractory Prostate Cancer Market

11.1. Asia-Pacific Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hormone Refractory Prostate Cancer Market

12.1. China Hormone Refractory Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hormone Refractory Prostate Cancer Market

13.1. India Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hormone Refractory Prostate Cancer Market

14.1. Japan Hormone Refractory Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

14.2. Japan Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hormone Refractory Prostate Cancer Market

15.1. Australia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hormone Refractory Prostate Cancer Market

16.1. Indonesia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hormone Refractory Prostate Cancer Market

17.1. South Korea Hormone Refractory Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

17.2. South Korea Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hormone Refractory Prostate Cancer Market

18.1. Taiwan Hormone Refractory Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

18.2. Taiwan Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hormone Refractory Prostate Cancer Market

19.1. South East Asia Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

19.2. South East Asia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hormone Refractory Prostate Cancer Market

20.1. Western Europe Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

20.2. Western Europe Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hormone Refractory Prostate Cancer Market

21.1. UK Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hormone Refractory Prostate Cancer Market

22.1. Germany Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hormone Refractory Prostate Cancer Market

23.1. France Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hormone Refractory Prostate Cancer Market

24.1. Italy Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hormone Refractory Prostate Cancer Market

25.1. Spain Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hormone Refractory Prostate Cancer Market

26.1. Eastern Europe Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

26.2. Eastern Europe Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hormone Refractory Prostate Cancer Market

27.1. Russia Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hormone Refractory Prostate Cancer Market

28.1. North America Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

28.2. North America Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hormone Refractory Prostate Cancer Market

29.1. USA Hormone Refractory Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

29.2. USA Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hormone Refractory Prostate Cancer Market

30.1. Canada Hormone Refractory Prostate Cancer Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

30.2. Canada Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hormone Refractory Prostate Cancer Market

31.1. South America Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

31.2. South America Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hormone Refractory Prostate Cancer Market

32.1. Brazil Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hormone Refractory Prostate Cancer Market

33.1. Middle East Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

33.2. Middle East Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hormone Refractory Prostate Cancer Market

34.1. Africa Hormone Refractory Prostate Cancer Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

34.2. Africa Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Segmentation By Distribution Channel, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hormone Refractory Prostate Cancer Market Regulatory and Investment Landscape

36. Hormone Refractory Prostate Cancer Market Competitive Landscape And Company Profiles

36.1. Hormone Refractory Prostate Cancer Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Hormone Refractory Prostate Cancer Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Hormone Refractory Prostate Cancer Market Company Profiles

36.3.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.2. Johnson And Johnson Overview, Products and Services, Strategy and Financial Analysis

36.3.3. F Hoffmann La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis

36.3.4. Merck And Co Inc Overview, Products and Services, Strategy and Financial Analysis

36.3.5. AbbVie Inc Overview, Products and Services, Strategy and Financial Analysis

37. Hormone Refractory Prostate Cancer Market Other Major And Innovative Companies

Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC

38. Global Hormone Refractory Prostate Cancer Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hormone Refractory Prostate Cancer Market

40. Hormone Refractory Prostate Cancer Market High Potential Countries, Segments and Strategies

40.1 Hormone Refractory Prostate Cancer Market In 2030 - Countries Offering Most New Opportunities

40.2 Hormone Refractory Prostate Cancer Market In 2030 - Segments Offering Most New Opportunities

40.3 Hormone Refractory Prostate Cancer Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Hormone Refractory Prostate Cancer Market, Overview Of Key Products - Product Examples
  • Table 2: Global Hormone Refractory Prostate Cancer Market Attractiveness, Factor-Wise Evaluation
  • Table 3: Global Hormone Refractory Prostate Cancer Market, Supply Chain Analysis
  • Table 4: Global Hormone Refractory Prostate Cancer Market, Major Raw Material Providers
  • Table 5: Global Hormone Refractory Prostate Cancer Market, Major Resource Providers
  • Table 6: Global Hormone Refractory Prostate Cancer Market, Major Manufacturers (Suppliers)
  • Table 7: Global Hormone Refractory Prostate Cancer Market, Major Distributors And Channel Partners
  • Table 8: Global Hormone Refractory Prostate Cancer Market, Key Technologies & Future Trends
  • Table 9: Global Hormone Refractory Prostate Cancer Market, Major Trends
  • Table 10: Global Hormone Refractory Prostate Cancer Market, Major End Users
  • Table 11: Global Hormone Refractory Prostate Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Table 12: Global Hormone Refractory Prostate Cancer Historic Market Growth, 2020-2025, $ Billion
  • Table 13: Global Hormone Refractory Prostate Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Table 14: Global Hormone Refractory Prostate Cancer Market - TAM, US$ Billion, 2025
  • Table 15: Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 16: Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 17: Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 18: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 19: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 20: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 21: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 22: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 23: Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 24: Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 25: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 26: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 27: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 28: China, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 29: China, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 30: China, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 31: India, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 32: India, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 33: India, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 34: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 35: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 36: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 37: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 38: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 39: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 40: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 41: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 42: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 43: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 44: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 45: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 46: Taiwan, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 47: Taiwan, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 48: Taiwan, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 49: South East Asia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 50: South East Asia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 51: South East Asia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 52: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 53: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 54: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 55: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 56: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 57: UK, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 58: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 59: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 60: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 61: France, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 62: France, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 63: France, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 64: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 65: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 66: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 67: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 68: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 69: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 70: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 71: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 72: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 73: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 74: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 75: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 76: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 77: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 78: North America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 79: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 80: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 81: USA, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 82: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 83: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 84: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 85: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 86: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 87: South America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 88: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 89: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 90: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 91: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 92: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 93: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 94: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 95: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 96: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Table 97: Global Hormone Refractory Prostate Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Table 98: Global Hormone Refractory Prostate Cancer Market - Company Scoring Matrix
  • Table 99: Pfizer Inc Financial Performance
  • Table 100: Johnson And Johnson Financial Performance
  • Table 101: F Hoffmann La Roche Ltd Financial Performance
  • Table 102: Merck And Co Inc Financial Performance
  • Table 103: AbbVie Inc Financial Performance
  • Table 104: Global Hormone Refractory Prostate Cancer Market, Competitive Benchmarking (In USD Billions)
  • Table 105: Global Hormone Refractory Prostate Cancer Market, Competitive Dashboard
  • Table 106: Global Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Table 107: Global, Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030
  • Table 108: Global, Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Table 109: Global, Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

List Of Figures

    Figure 1: Global Hormone Refractory Prostate Cancer Market, Overview Of Key Products - Product Examples
  • Figure 2: Global Hormone Refractory Prostate Cancer Market Attractiveness, Factor-Wise Evaluation
  • Figure 3: Global Hormone Refractory Prostate Cancer Market, Supply Chain Analysis
  • Figure 4: Global Hormone Refractory Prostate Cancer Market, Major Raw Material Providers
  • Figure 5: Global Hormone Refractory Prostate Cancer Market, Major Resource Providers
  • Figure 6: Global Hormone Refractory Prostate Cancer Market, Major Manufacturers (Suppliers)
  • Figure 7: Global Hormone Refractory Prostate Cancer Market, Major Distributors And Channel Partners
  • Figure 8: Global Hormone Refractory Prostate Cancer Market, Key Technologies & Future Trends
  • Figure 9: Global Hormone Refractory Prostate Cancer Market, Major Trends
  • Figure 10: Global Hormone Refractory Prostate Cancer Market, Major End Users
  • Figure 11: Global Hormone Refractory Prostate Cancer Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis
  • Figure 12: Global Hormone Refractory Prostate Cancer Historic Market Growth, 2020-2025, $ Billion
  • Figure 13: Global Hormone Refractory Prostate Cancer Forecast Market Growth, 2025-2030F, 2035F, $ Billion
  • Figure 14: Global Hormone Refractory Prostate Cancer Market - TAM, US$ Billion, 2025
  • Figure 15: Global Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 16: Global Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 17: Global Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 18: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 19: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Hormonal Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 20: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Immunotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 21: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 22: Global Hormone Refractory Prostate Cancer Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 23: Global Hormone Refractory Prostate Cancer Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 24: Global Hormone Refractory Prostate Cancer Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 25: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 26: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 27: Asia-Pacific, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 28: China, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 29: China, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 30: China, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 31: India, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 32: India, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 33: India, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 34: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 35: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 36: Japan, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 37: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 38: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 39: Australia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 40: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 41: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 42: Indonesia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 43: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 44: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 45: South Korea, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 46: Taiwan, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 47: Taiwan, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 48: Taiwan, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 49: South East Asia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 50: South East Asia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 51: South East Asia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 52: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 53: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 54: Western Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 55: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 56: UK, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 57: UK, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 58: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 59: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 60: Germany, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 61: France, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 62: France, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 63: France, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 64: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 65: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 66: Italy, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 67: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 68: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 69: Spain, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 70: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 71: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 72: Eastern Europe, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 73: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 74: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 75: Russia, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 76: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 77: North America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 78: North America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 79: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 80: USA, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 81: USA, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 82: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 83: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 84: Canada, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 85: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 86: South America, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 87: South America, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 88: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 89: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 90: Brazil, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 91: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 92: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 93: Middle East, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 94: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Treatment Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 95: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 96: Africa, Hormone Refractory Prostate Cancer Market, Segmentation By End-User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Figure 97: Global Hormone Refractory Prostate Cancer Key Competitor Estimated Market Shares, 2024, Percentage (%)
  • Figure 98: Global Hormone Refractory Prostate Cancer Market - Company Scoring Matrix
  • Figure 99: Pfizer Inc Financial Performance
  • Figure 100: Johnson And Johnson Financial Performance
  • Figure 101: F Hoffmann La Roche Ltd Financial Performance
  • Figure 102: Merck And Co Inc Financial Performance
  • Figure 103: AbbVie Inc Financial Performance
  • Figure 104: Global Hormone Refractory Prostate Cancer Market, Competitive Benchmarking (In USD Billions)
  • Figure 105: Global Hormone Refractory Prostate Cancer Market, Competitive Dashboard
  • Figure 106: Global Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), 2025 – 2030 By Country
  • Figure 107: Global, Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), Segmentation By Treatment Type, 2025 – 2030
  • Figure 108: Global, Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), Segmentation By Distribution Channel, 2025 – 2030
  • Figure 109: Global, Hormone Refractory Prostate Cancer Market Size Gain ($ Billion), Segmentation By End-User, 2025 – 2030

Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

Read More About Global Acute Care Telemedicine Market Forecast to Reach $66.59 Billion by 2029, Driven by 17.7% CAGR

2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Assistive Technology For Low Vision Market Outlook: Regional Trends and Growth Forecast

Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Read More About Global Biotechnology And Pharmaceutical Services Outsourcing Market Forecast to Reach $94.91 Billion by 2029, Driven by 7.2% CAGR

Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

Read More About Cancer Treatment Facilities Market Revenue Outlook: Strategic Insights and Forecast to 2029

CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Read More About CAGR of 10.4% Projected for Catastrophic Antiphospholipid Syndrome Market From 2025 to 2029

Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

Read More About Latest Market Developments in Clinical Risk Grouping Solution Industry: Forecast 2025–2029

2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Read More About 2025–2029 Clinical Trial Investigative Site Network Market Outlook: Regional Trends and Growth Forecast

Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Read More About Future Demand and Leading Companies Shaping the Common Cold Market to 2029

Prostate Cancer Drugs Market Report 2026 - Global Outlook – By Type (Hormone Sensitive Prostate Cancer, Hormone Refractory Prostate Cancer), By Therapy (Hormonal Therapy, Chemotherapy, Immunotherapy, Targeted Therapy), B...

Prostate Cancer Diagnostics Market Report 2026 - Global Outlook – By Products (Instruments, Reagents And Consumables, Accessories), By Test Type (Preliminary Tests, Confirmatory Tests), By Prostate Cancer (Squamous Cell ...

Prostate Cancer Nuclear Medicine Diagnostics Market Report 2026 - Global Outlook – By Type (Single Photon Emission Computed Tomography (SPECT), Photon Emission Computed Tomography (PET)), By Test Type (Preliminary Tests,...

Benign Prostatic Hyperplasia (BPH) Treatment Devices And Equipment Market Report 2026 - Global Outlook – By Product (Resectoscopes, Radiofrequency Ablation Device, Urology Lasers, Prostatic Stents, Implants), By Procedur...

Drugs For Benign Prostatic hypertrophy Market Report 2026 - Global Outlook – By Type (Alpha Blocker, 5-alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, Other Types), By Distribution Channel (Hospital Pharmacies,...

Urinary Tract Cancer Market Report 2026 - Global Outlook – By Cancer Type (Bladder Cancer, Urethral Cancer, Ureteric And Renal Pelvic Cancer), By Treatment (Chemotherapy, Intravesical Therapy, Radiation Therapy, Surgery)...

Prostate Specific Antigen (PSA) Test Market Report 2026 - Global Outlook – By Type (Clinical Laboratory Improvement Amendments (CLIA), Enzyme-Linked Immunosorbent Assay (ELISA), Fluorescence Immunoassay (FIA), Other Type...

Hormone Therapy Market Report 2026 - Global Outlook – By Therapy (Estrogen Hormone Replacement, Growth Hormone Replacement, Thyroid Hormone Replacement, Testosterone Replacement), By Route Of Administration (Oral, Parent...

Frequently Asked Questions

The Hormone Refractory Prostate Cancer market was valued at $8.12 billion in 2025, increased to $8.95 billion in 2026, and is projected to reach $13.09 billion by 2030.

The global Hormone Refractory Prostate Cancer market is expected to grow at a CAGR of 10.0% from 2026 to 2035 to reach $13.09 billion by 2035.

Some Key Players in the Hormone Refractory Prostate Cancer market Include, Pfizer Inc, Johnson And Johnson, F Hoffmann La Roche Ltd, Merck And Co Inc, AbbVie Inc, Bayer AG, Sanofi SA, Bristol Myers Squibb Company, Novartis AG, AstraZeneca Plc, Eli Lilly And Company, Amgen Inc, Astellas Pharma Inc, Ipsen Pharma, Exelixis Inc, Orion Corporation, Lantheus Holdings Inc, Clovis Oncology Inc, Telix Pharmaceuticals, Dendreon Pharmaceuticals LLC, Janssen Pharmaceuticals Inc, Bayer Healthcare Pharmaceuticals Inc .

Major trend in this market includes: Advancement In Targeted Radioligand Therapy Gains Ground In Advancing Treatment For Resistant Prostate Cancer. For further insights on this market. request a sample here

North America was the largest region in the hormone-refractory prostate cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hormone refractory prostate cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customer representative image Book your 30 minutes free consultation with our research experts
Contact Us